Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.

Recombinant thrombomodulin safely improves acute exacerbation in idiopathic interstitial pneumonias

12 Jul 2019
Smoking is one cause of idiopathic pulmonary fibrosis, apart from hereditary factors and inhalation of certain types of dust.

Recombinant human soluble thrombomodulin (rhTM) is a safe and effective treatment for acute exacerbation (AE) in other idiopathic interstitial pneumonias (IIP), a recent study has shown.

AE-IIP patients treated with rhTM had a 90-day survival rate of 66.7 percent (26/39), while those who were not treated with rhTM had a survival rate of 47.5 percent (29/61). After adjusting for imbalances, a significant association was found between rhTM therapy and reduced mortality (adjusted hazard ratio, 0.453, 95 percent CI, 0.237–0.864; p=0.0163).

Adverse events occurred in 17.9 percent (7/39) of patients treated with rhTM and in 19.7 percent (12/61) of those who did not receive rhTM, which were comparable in both groups (p=1.0). In addition, the rhTM group reported two cases of bleeding events.

Future randomized controlled trials are warranted to confirm these findings.

This prospective, single-arm, open-label, multicentre cohort study retrospectively registered 61 patients with AE-IIP who were treated with conventional therapy between 2011 and 2013 (control group) and prospectively included 39 patients with AE-IIP who received conventional therapy and rhTM (380 U/kg/day for 6 days) between 2014 and 2016 (rhTM group).

The investigators conducted an adjusted mortality analysis for 90-day survival with weighted Cox proportional regression models using inverse probability of treatment weighting to reduce potential confounding in treatment comparisons. Weights were derived from propensity score estimated using a multivariable logistic regression analysis, including potential confounders.

“AE in idiopathic pulmonary fibrosis or other IIP is a poor prognostic event despite conventional therapy with corticosteroids and/or immunosuppressants,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.